Evzen Machytka

Evzen Machytka

Auto-generated profile, based on publicly available information

Evzen Machytka

Department of Surgical Studies, Faculty of Medicine, University Hospital Ostrava, Ostrava, Czech Republic

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
EMEvžen Machytka
Evžen Machytka
MBMarek Bužga
Marek Bužga
PZPavel Zonca
Pavel Zonca
DLDavid B. Lautz
David B. Lautz
MRMarvin Ryou
Marvin Ryou
CTChristopher C. Thompson
Christopher C. Thompson

12 December 2016 in Endoscopy
Verified
Journal Article
Closed access
PDF file
EMEvzen Machytka
Evzen Machytka
SGShantanu Gaur
Shantanu Gaur
RCRam Chuttani
Ram Chuttani
MBMartina Bojkova
Martina Bojkova
TKTomas Kupka
Tomas Kupka
IRIoannis Raftopoulos
Ioannis Raftopoulos
Background and study aims: Conventional gastric balloons for weight loss require endoscopy for placement and removal. The Elipse device is swallowed, resides in the stomach for 4 months, and is then expelled. The objectives of this study were to assess the safety of Elipse and to measure its effects on weight loss, metabolic parameters, and quality of life. Methods: Each participant swallowed one Elipse device, which was filled with 550 mL of filling fluid through a thin delivery catheter that was then removed. Weight was measured every 2 weeks, and metabolic parameters and quality of life were assessed at baseline and at trial exit. Results: 34 patients, with a mean body mass index of 34.8 kg/m2, were enrolled. All 34 patients successfully swallowed the Elipse device. All adverse events were either self-limiting or resolved with medication. All balloons were safely excreted. At 4 months, the mean percent total body weight loss was 10 %. Mean waist circumference was reduced by 8.4 cm. Improvements were also seen in hemoglobin A1c, triglycerides, low density lipoprotein, and blood pressure. At trial exit, quality of life measures had improved across all domains. Conclusion: These results demonstrate clinically significant weight loss with the Elipse, the first procedureless gastric balloon. The weight loss was similar to that seen in previous studies of endoscopically placed balloons. In addition, Elipse therapy led to improvements in waist circumference, several metabolic parameters, and overall quality of life. ClinicalTrials.gov identifier: NCT 02802007.


16 June 2022 in Gastroenterology
Verified
Journal Article
Closed access
EMEvzen Machytka
Evzen Machytka
MBMarek Bužga
Marek Bužga
ZŠZdeněk Švagera
Zdeněk Švagera
KJKarolina Janochova
Karolina Janochova
DSDavid Steskal
David Steskal
CTChristopher C. Thompson
Christopher C. Thompson